Correction To: RE-MIND2: Comparative Effectiveness of Tafasitamab Plus Lenalidomide Versus Polatuzumab Vedotin/bendamustine/rituximab (pola-BR), CAR-T Therapies, and Lenalidomide/rituximab (R2) Based on Real-world Data in Patients with Relapsed/refractory Diffuse Large B-cell Lymphoma
